VNDA (Vanda Pharmaceuticals Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by VNDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Anne Sempowski Ward | Director | A | — | — |
| 2026-06-08 | RICHARD W DUGAN | Director | A | — | — |
| 2026-06-08 | Tage Honore | Director | A | — | — |
| 2026-06-08 | Phaedra Chrousos | Director | A | — | — |
| 2026-06-08 | Stephen Ray Mitchell | Director | A | — | — |
| 2026-06-08 | Charles Cliff Duncan | Director | A | — | — |
| 2026-06-08 | Daniel Patrick McGuire | SVP, GC and Secretary | A | — | — |
| 2026-05-20 | Stephen Ray Mitchell | Director | G | — | — |
| 2026-04-24 | Charles Cliff Duncan | Director | A | — | — |
| 2026-03-04 | Mihael Hristos Polymeropoulos | President and CEO | Sell | — | — |
| 2026-03-04 | Timothy Williams | SVP & General Counsel | Sell | — | — |
| 2026-03-04 | Gunther Birznieks | SVP, Business Development | Sell | — | — |
| 2026-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell | — | — |
| 2026-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell | — | — |
| 2026-02-24 | Tage Honore | Director | Sell | — | — |
| 2026-02-19 | Timothy Williams | SVP & General Counsel | A | — | — |
| 2026-02-19 | Mihael Hristos Polymeropoulos | President and CEO | A | — | — |
| 2026-02-19 | Joakim Wijkstrom | SVP, Chief Marketing Officer | A | — | — |
| 2026-02-19 | Gunther Birznieks | SVP, Business Development | A | — | — |
| 2026-02-19 | Kevin Patrick Moran | SVP, CFO & Treasurer | A | — | — |
| 2025-08-08 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-06-16 | Stephen Ray Mitchell | Director | Sell | — | — |
| 2025-06-09 | Phaedra Chrousos | Director | A | — | — |
| 2025-06-09 | Tage Honore | Director | A | — | — |
| 2025-06-09 | RICHARD W DUGAN | Director | A | — | — |
| 2025-06-09 | Stephen Ray Mitchell | Director | A | — | — |
| 2025-06-09 | Anne Sempowski Ward | Director | A | — | — |
| 2025-05-21 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-05-19 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-03-06 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-03-05 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | F | — | — |
| 2025-03-04 | Timothy Williams | SVP & General Counsel | F | — | — |
| 2025-03-04 | Mihael Hristos Polymeropoulos | President and CEO | MIXED | — | — |
| 2025-03-04 | Gunther Birznieks | SVP, Business Development | F | — | — |
| 2025-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | F | — | — |
| 2025-02-28 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-02-27 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-02-26 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-02-25 | Mihael Hristos Polymeropoulos | President and CEO | Buy | — | — |
| 2025-02-24 | Kevin Patrick Moran | SVP, CFO & Treasurer | Buy | — | — |
| 2025-02-20 | Timothy Williams | SVP & General Counsel | A | — | — |
| 2025-02-20 | Joakim Wijkstrom | SVP, Chief Marketing Officer | A | — | — |
| 2025-02-20 | Kevin Patrick Moran | SVP, CFO & Treasurer | A | — | — |
| 2025-02-20 | Gunther Birznieks | SVP, Business Development | A | — | — |
| 2025-02-20 | Mihael Hristos Polymeropoulos | President and CEO | A | — | — |
| 2024-11-18 | Stephen Ray Mitchell | Director | Sell | — | — |
| 2024-07-29 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell | — | — |
| 2024-05-24 | Phaedra Chrousos | Director | A | — | — |
| 2024-05-21 | Anne Sempowski Ward | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,065,852 | — |
| — | 10%+ Owner | 2,884,671 | — |
| — | 10%+ Owner | 2,715,852 | — |
| — | President and CEO | 2,704,496 | — |
| — | 10%+ Owner | 2,660,207 | — |
| — | 10%+ Owner | 2,152,952 | — |
| — | 10%+ Owner | 850,778 | — |
| — | SVP, Business Development | 494,197 | — |
| — | SVP, CFO & Treasurer | 412,015 | — |
| — | SVP & General Counsel | 377,450 | — |
| — | SVP, Chief Marketing Officer | 333,469 | — |
| — | Director | 219,054 | — |
| — | EVP & Chief Financial Officer | 186,869 | — |
| — | Sr. VP, Chief Business Officer | 168,279 | — |
| — | SVP & Chief Commercial Officer | 165,384 | — |
| — | Director | 164,950 | — |
| — | Director | 160,667 | — |
| — | Director | 135,069 | — |
| — | SVP, General Counsel & Sec. | 118,733 | — |
| — | Director | 112,846 | — |
| — | SVP, GC and Secretary | 109,982 | — |
| — | Chief Corp. Affairs Officer | 98,804 | — |
| — | Director | 98,701 | — |
| — | Director | 69,505 | — |
| — | SVP & Chief Medical Officer | 53,165 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VNDA quote page; the site-wide leaderboard is on the insider transactions hub.